Cargando…
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
Fifty-two previously untreated patients with advanced non-small-cell lung cancer (NSCLC) were treated on a 14 day cycle with cisplatin (60 mg m-2 i.v.) and vindesine (3 mg m-2 i.v.) on day 1, followed by a 3 day continuous infusion of 5-fluorouracil (800 mg m-2 day-1) starting on day 8. An overall r...
Autores principales: | Nakano, T., Ikegami, H., Nakamura, S., Kawase, T., Nishikawa, H., Yokota, S., Yoshida, M., Tachibana, T., Igarashi, T., Komuta, K., Higashino, K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074391/ https://www.ncbi.nlm.nih.gov/pubmed/8624270 |
Ejemplares similares
-
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
por: Pectasides, D., et al.
Publicado: (1989) -
Phase I study of 21 days continuous infusion with vindesine.
por: de Vries, E. G., et al.
Publicado: (1989) -
A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.
por: Woods, R. L., et al.
Publicado: (1990) -
Characterisation of a vindesine-resistant human small-cell lung cancer cell line.
por: Ohta, S., et al.
Publicado: (1993) -
A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
por: Furuse, K., et al.
Publicado: (1997)